The efficacy of nintedanib in 158 patients with idiopathic pulmonary fibrosis in real-world settings: A multicenter retrospective study

Masaki Dobashi¹, Hisashi Tanaka¹, Kageaki Taima¹, Masamichi Itoga¹, Yoshiko Ishioka¹, Toshihiro Shiratori¹, Fumihiko Okumura¹, Chiori Tabe¹, Yoshihito Tanaka², Takeshi Morimoto³, Yukihiro Hasegawa³, Hideo Yasugahira⁴, Koichi Okudera⁵, Shingo Takanashi⁶ and Sadatomo Tasaka¹

Abstract

Background: The INPULSIS trials revealed that nintedanib reduced the decline in lung function in patients with idiopathic pulmonary fibrosis. We aimed to evaluate the efficacy and safety of nintedanib in Japanese idiopathic pulmonary fibrosis patients in real-world settings.

Method: Medical records of idiopathic pulmonary fibrosis patients, who received treatment with nintedanib in five institutions between July 2015 and June 2017, were reviewed. Patients with % forced vital capacity ≥ 50% and % predicted diffusing capacity of the lung carbon monoxide ≥ 30% were classified as the moderate group and those with more impaired lung functions as the severe group.

Result: Among 158 patients analyzed, 132 (84.6%) were classified as the moderate group and 26 (15.4%) as the severe group. In the moderate group, changes in forced vital capacity in 12 months were significantly different between before and after nintedanib administration (−253 ± 163 vs −125 ± 235 mL; p = 0.0027). In contrast, changes in forced vital capacity in 12 months were not significantly changed by nintedanib treatment in the severe group (−353 ± 250 vs −112 ± 341 mL; p = 0.2374). Incidence of acute exacerbation was higher in the severe group than in the moderate group (30.8% vs 18.9%).

The overall survival of the moderate and the severe groups was 17.2 and 10.1 months.

Conclusion: In real-world practice, nintedanib showed comparable efficacy to those observed in previous trials. In the severe group, the efficacy of nintedanib might be limited.

Keywords

Idiopathic pulmonary fibrosis, nintedanib, forced vital capacity, acute exacerbation, long-term oxygen therapy

Date received: 21 December 2020; accepted: 19 May 2021

¹Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Aomori, Japan
²Department of Respiratory Medicine, Hirosaki National Hospital, Aomori, Japan
³Department of Respiratory Medicine, Aomori Prefectural Central Hospital, Aomori, Japan
⁴Department of Respiratory Medicine, Hachinohe City Hospital, Aomori, Japan
⁵Department of Respiratory Medicine, Hirosaki Central Hospital, Aomori, Japan
⁶Health Administration Center, Hirosaki University, Aomori, Japan

Corresponding author:
Hisashi Tanaka, Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan.
Email: xyghx335@gmail.com
**Background**

Idiopathic pulmonary fibrosis (IPF) is a debilitating, progressive, fibrosing lung disease caused by unknown etiology.\(^1\) The prognosis of IPF is poor, with median overall survival ranging reported 2–4 years after diagnosis.\(^2,3\) Over the past 5 years, the introduction of novel antifibrotic agents in the form of pirfenidone and nintedanib has changed the management of IPF and provided improvement of clinical outcome. Several fibrotic mediators, including fibroblast growth factors (FGFs), platelet-derived growth factors (PDGFs), and transforming growth factor beta, are associated with the pathogenesis of IPF.\(^4,5\) Nintedanib is a potent, oral, small-molecule tyrosine kinase inhibitor that blocks the kinase activity of a variety of receptors, such as vascular endothelial growth factor (VEGF) receptor,\(^6\) PDGF receptor, and FGF receptor.\(^7\) It inhibits the intracellular signaling pathways that are crucial for the proliferation, migration, and transformation of lung fibroblasts.\(^6,8\) A phase II TOMORROW trial and two phase III trials (INPULSIS-1 and -2) have shown significant reductions in the rate of decline in forced vital capacity (FVC) and the incidence of acute exacerbation over a 52-week treatment period in IPF patients treated with nintedanib.\(^9,10\) In Japan, nintedanib was launched in 2015. In these clinical trials, however, patients, who had %FVC $<$ 50% and % predicted diffusing capacity of the lungs for carbon monoxide (DL\(_{CO}\)) $<$ 30%, were excluded, which makes the efficacy of nintedanib in those with severe IPF unclear. Moreover, the number of IPF patients who received long-term oxygen therapy (LTOT) was less than 10% of the study subjects, making the efficacy and safety of nintedanib in such patients unclear. In this study, we aimed to evaluate the efficacy and safety of nintedanib for Japanese IPF patients in real-world practice.

**Patients and methods**

**Study design**

Our study was performed in five institutions in Aomori, Japan. This study was conducted between July 2015 and June 2017. This study is a retrospective study, and we did not set a clear number of cases. IPF patients who have received nintedanib were included. We reviewed the medical records of all the patients who were treated with nintedanib at the participating hospitals. We made a diagnosis of IPF based on the ATS/ERS/JRS/ALAT IPF guideline of 2011.\(^1\) Patients with %FVC $\geq$ 50% and %DL\(_{CO}\) $\geq$ 30% were classified as the moderate group and those with %FVC $<50\%$ or %DL\(_{CO}\) $<30\%$ as the severe group. The study was performed according to the protocol approved by the ethics committee of each participating hospital. The ethics committee of Hirosaki University approved this study (approval number: 2018-1203). Because this was a retrospective cohort study, informed consent was waived. Opt out was posted on our website.

**Evaluation and statistical analysis**

The clinical data were expressed as mean ± standard deviation (SD). We compared the baseline characteristics, lung function data including the rate of decline in FVC, frequency of adverse events, and survival rate between the two groups. Acute exacerbations of IPF are defined as episodes of respiratory worsening that occur within 1 month and cannot be explained by other reasons such as pneumonia, pulmonary embolism, pneumothorax, or cardiac failure. We used two severity criteria of IPF, the gender, age, physiology (GAP) staging.\(^11\) The GAP score was calculated by the following status: gender (0: female; 1: male), age (0: $\leq$ 60; 1: 61–65; 2: $>$65), %FVC (0: $>$75%; 1: 50%–75%; 2: $<$50%), and %DL\(_{CO}\) (0: $>$55%; 1: 36%–55%; 2: $<$35%; 3: cannot perform). The total point score is used to classify patients as stage I: 0–3 points, stage II: 4–5 points, or stage III: 6–8 points. All statistical analyses were performed using JMP 13 (SAS Institute, Cary, NC). Overall survival (OS) and the ratio of acute exacerbation were estimated using the Kaplan–Meier method. The toxicity profiles were graded by Common Terminology Criteria for Adverse Events v5.0 (CTCAE). A statistical significance was considered when p value was less than 0.05.

**Results**

**Patient characteristics**

A total of 177 patients with IPF were administrated nintedanib at the participating hospitals between July 2015 and June 2017. Nineteen patients were excluded from analysis due to the lack of initial spirometry data. Finally, a total of 158 patients were subjected to analysis (Figure 1). In 45 patients, the rate of FVC decline over 12 months (ΔFVC) was evaluated both before and after the introduction of nintedanib. One hundred thirty-two patients (84.6%) were classified as the moderate group and 26 (15.4%) as the severe group. Patient demographics and baseline characteristics were summarized in Table 1. There were no significant differences between the two groups in age, height, smoking status, and serum levels of lactate dehydrogenase (LDH) and sialylated carbohydrate antigen KL-6 (KL-6). On the other hand, there were significant differences in body weight (59.3 ± 11.6 kg in the moderate group vs 52.2 ± 11.8 kg in the severe group; p = 0.0049), body mass index (BMI) (23.2 ± 3.7 vs 20.9 ± 4.0 kg/m\(^2\); p = 0.0049), and GAP stage (p < 0.0001). The ratio of patients who received LTOT (16.7% vs 53.8%; p < 0.0001) and precedent pharmacotherapy (37.1% vs 61.5%; p = 0.0207) were significantly higher in the severe group.

**Rate of decline in FVC**

ΔFVC was calculated from spirometry data conducted before and 12 months after the introduction of nintedanib. In...
the moderate group, ΔFVC was significantly different between before and after the introduction of nintedanib (−253.2 ± 163.2 vs −124.5 ± 235.3 mL; p = 0.0057). In the severe group, there was no significant difference in ΔFVC between before and after the treatment (−353.4 ± 250.4 vs −111.6 ± 341.4 mL; p = 0.2374) (Figure 2(a) and (b)).

**Survival outcome**

The OS was 17.2 months in the moderate group and 10.1 months in the severe group, which was significantly different (p = 0.013) (Figure 3(a)). One-year survival rate was 68.2% in the moderate group and 44.6% in the severe group. We conducted an additional analysis of OS according to GAP model severity.

**Table 1.** Baseline Characteristics of Total 158 Patients.

|                                | Total (n = 158) | Moderate Group (n = 132) | Severe Group (n = 26) | p value |
|--------------------------------|----------------|-------------------------|----------------------|---------|
| Age (years)                    | 71.7 ± 8.6     | 72.0 ± 8.0              | 69.9 ± 11.3          | 0.2484  |
| Male/female                    | 116/42         | 98/34                   | 18/8                 | 0.0015  |
| Height (cm)                    | 159.5 ± 9.3    | 159.7 ± 8.8             | 158.1 ± 11.8         | 0.4224  |
| Body weight (kg)               | 58.2 ± 11.9    | 59.3 ± 11.6             | 52.2 ± 11.8          | 0.0049  |
| BMI (kg/m²)                    | 22.8 ± 3.8     | 23.2 ± 3.7              | 20.9 ± 4.0           | 0.0049  |
| Smoking status (+/-)           | 106/52         | 89/43                   | 17/9                 | 0.8397  |
| GAP stage (I/II/III/unknown)   | 60/58/15/25    | 59/47/1/25              | 1/11/1/4/0           | <0.0001 |
| LTOT                           | 36 (22.8%)     | 22 (16.7%)              | 14 (53.8%)           | <0.0001 |
| LDH (U/L)                      | 254.4 ± 93.5   | 254.6 ± 98.5            | 253.1 ± 64.0         | 0.9402  |
| KL-6 (U/mL)                    | 1346.3 ± 1055.8| 1346.9 ± 1115.8         | 1343.1 ± 709.8       | 0.9896  |
| FVC (mL)                       | 2230.2 ± 794.1 | 2365.2 ± 747.5          | 1544.6 ± 669.2       | <0.0001 |
| %FVC (%)                       | 73.2 ± 20.6    | 77.9 ± 17.8             | 49.9 ± 17.9          | <0.0001 |
| %DLCO (%)                      | 60.1 ± 25.1    | 64.5 ± 23.6             | 32.5 ± 14.5          | <0.0001 |
| Previous treatment             | 65 (41.1%)     | 49 (37.1%)              | 16 (61.5%)           | 0.0207  |
| COPD                           | 13 (8.2%)      | 12 (9.1%)               | 1 (3.8%)             | 0.3329  |
| Cancer complications           | 30 (20.2%)     | 29 (22.0%)              | 3 (11.5%)            | 0.2016  |
| Pulmonary artery diameter      | 29.61 ± 0.39   | 29.34 ± 0.42            | 31.08 ± 0.96         | 0.1003  |

COPD: chronic obstructive pulmonary disease; BMI: body mass index; DLCO: diffusing capacity of the lung carbon monoxide; FVC: forced vital capacity; GAP: gender, age, physiology; KL-6: sialylated carbohydrate antigen KL-6; LDH: lactate dehydrogenase; LTOT: long-term oxygen therapy.
Survival rate was higher in patients with an early stage of IPF (Supplemental Figure 1). The 1-year survival rates were 73.0% in stage I, 61.7% in stage II, and 38.6% in stage III.

**Acute exacerbation**

The incidence of acute exacerbation in the severe group was significantly higher than in the moderate group (Figure 3(b)). During 52 weeks after the introduction of nintedanib, acute exacerbation occurred in 12.3% of the moderate group and 27.3% of the severe group ($p=0.042$). The incidence rate of acute exacerbation was 18.9% in the moderate group (mean follow-up time: 563 days) and 30.8% in the severe group (mean follow-up time: 550 days) (Figure 4(a)). Figure 4(b) shows the rate of acute exacerbation in patients who received LTOT. The rate of acute exacerbation in the severe group patients who received LTOT was as high as 44.4%. Table 2 shows the association of baseline patient parameters with acute exacerbations. Serum LDH and LTOT showed a significant difference in the rate of acute exacerbations between the moderate and severe groups. We conducted an additional analysis of acute exacerbation according to GAP severity. There were no statistically significant differences in the rate of acute exacerbation between the patients with different stages of the disease (Supplemental Figure 2).

**Safety**

Table 3 shows the adverse events (AEs) observed during the treatment with nintedanib. Any AEs were observed in 136 patients (86.1%). AEs of CTCAE grade 3 and 4 were observed in 17 patients (10.8%). The most common AEs were diarrhea, which was observed in 76 patients (57.8%) in the moderate group and 14 (53.8%) in the severe group, followed by liver disorder (39.4% in the moderate group and 46.2% in the severe group), anorexia (34.8% in the moderate group and 26.9% in the severe group), and nausea (12.9% in the moderate group and 12.9% in the severe group). Malaise was significantly more frequent in the severe group than in the moderate group (8.3% in the moderate group and 23.1% in the severe group; $p=0.027$).

Twenty-eight patients needed to reduce the dose of nintedanib. Liver disorder was the most common reason for dose reduction of nintedanib (40.5%).

The discontinuation rate was 47.5% (75/158) in all patients. The reasons for discontinuation were toxicity (37.3%), death due to disease progression (24.0%), acute exacerbation (16.0%), insufficient efficacy (5.3%), and others (17.3%). Discontinuation rates were not significantly different between the moderate group and severe group (47.4% vs 50%; $p=0.77$).

**Discussion**

The present study is one of the largest real-world studies that evaluated the efficacy and safety of nintedanib for Japanese IPF patients including those who did not meet the inclusion criteria of the clinical trials. Moreover, this is the first report that showed the rate of acute exacerbation in IPF patients receiving LTOT during treatment with nintedanib.
In this study, $\Delta$FVC in 12 months was significantly reduced after nintedanib administration in patients with moderate IPF, which was comparable with the data shown in phase III trials. In INPULSIS-1 and -2 trials, nintedanib reduced the rate of decline in FVC by 125.3 and 93.7 mL/year, respectively. In addition, $\Delta$FVC was reduced after the introduction of nintedanib in four of five patients with severe IPF although the difference was not statistically significant. In the recent INPULSIS-ON study, patients were classified according to the baseline FVC % predicted ($\leq 50\%$ or $>50\%)$. It was revealed that there were no significant differences in the decline of FVC between the two subgroups. However, the number of patients with FVC $\leq 50\%$ predicted was only 24, which made the efficacy of nintedanib in patients with more advanced IPF unclear. Recently, Yoon et al. reported a prospective study that evaluated the efficacy and safety of nintedanib in patients with advanced and nonadvanced IPF. A significant reduction of FVC decline rate was observed even in those with advanced disease ($n=45$). In another retrospective study, Abe et al. reported the effectiveness of nintedanib in patients with severe IPF. A total of 51 patients received nintedanib (34 with mild-to-moderate IPF and 17 with severe IPF). Because $\Delta$FVC was
significantly reduced after the introduction of nintedanib, they concluded that the efficacy of nintedanib might be regardless of the disease severity. However, the frequency of side effects tended to be higher and the prognosis was significantly worse in the severe group. Moreover, Tzouvelekis et al. reported that nintedanib was as effective in patients with %FVC < 50% as in those with %FVC > 50%.

In the present study, the annual rate of acute exacerbation during 12 months in patients with moderate IPF was 12.3%, which was higher than the numbers shown in phase III trials. We considered the following reasons for the higher incidence rate of acute exacerbation. First, in our study, the number of patients who had been receiving medical treatment including pirfenidone was as high as 37.1% in the moderate group. Second, the number of patients who received LTOT was also high in the moderate group. These factors may have affected the frequency of acute exacerbations. In fact, the annual incidence of acute exacerbation was 27.3% in the severe group and 44.4% in those receiving LTOT, which was considerably high. Acute exacerbation is the leading cause of death of IPF patients in Japan, and its incidence has been reported to be 5%–19%. The pooled analysis of the data from the INPULSIS trials showed that a lower percentage of the subjects treated with nintedanib experienced acute exacerbations in a 52-week period compared with those in the placebo group. Therefore, we considered that there might be some effective cases even in those with severe IPF, although the patients on LTOT might receive little benefit from the treatment.

The incidence of AEs in our study was similar to that reported in the INPULSIS studies. Incident rates for diarrhea, nausea, and malaise were comparable with those observed in the trials. Yoon et al. reported that the frequencies of diarrhea and anorexia were 50.0% and 45.4%, respectively, which were similar to those in our study. On the other hand, we observed liver disorder in 40.5% of the patients, which was high than that shown in the

### Table 2. Association of Baseline Patient Parameters With Acute Exacerbations.

| Event of acute exacerbation | p value |
|-----------------------------|---------|
| (-)                         | (+)     |
| Age (years)                | 71.8 ± 0.7 | 71.0 ± 1.5 | 0.62 |
| Male/female                | 91/34   | 8/25     | 0.93 |
| Height (cm)                | 159.5 ± 0.8 | 159.4 ± 1.6 | 0.98 |
| Body weight (kg)           | 58.1 ± 1.1 | 58.3 ± 2.1 | 0.93 |
| BMI (kg/m²)                | 22.8 ± 0.3 | 22.8 ± 0.7 | 0.98 |
| Smoking status (+/-)       | 42/83   | 10/23    | 0.72 |
| GAP stage (I/II/III/unknown) | 51/42/11/21 | 9/16/4/4 | 0.35 |
| LDH (U/L)                  | 244.6 ± 8.4 | 291.0 ± 16.2 | 0.01 |
| KL-6 (U/mL)                | 1324.8 ± 98.3 | 1426.5 ± 190.1 | 0.64 |
| FVC (mL)                   | 2271.3 ± 70.9 | 2074.5 ± 140.0 | 0.21 |
| %FVC (%)                   | 74.6 ± 1.8 | 67.8 ± 3.6 | 0.09 |
| %DLCO (%)                  | 62.0 ± 2.5 | 53.2 ± 4.8 | 0.10 |
| Previous treatment         | 33 (26.4%) | 13 (39.4%) | 0.15 |

BMI: body mass index; DLCO: diffusing capacity of the lung carbon monoxide; FVC: forced vital capacity; GAP: gender, age, physiology; KL-6: sialylated carbohydrate antigen KL-6; LDH: lactate dehydrogenase; LTOT: long-term oxygen therapy.

### Table 3. Toxicity in Patients Treated With Nintedanib.

| Adverse Events | Total (n = 158) | Moderate Group (n = 132) | Severe Group (n = 26) | p value |
|----------------|-----------------|--------------------------|-----------------------|---------|
| CTCAE grade   | All ≥3          | All ≥3                   | All ≥3                |         |
| All adverse events | 136 (86.1%) | 17 (10.8%) | 114 (86.4%) | 15 (11.4%) | 22 (84.6%) | 2 (7.7%) | 0.81 |
| Diarrhea      | 90 (57.0%)     | 3 (1.9%)     | 76 (57.8%)  | 3 (2.3%)  | 14 (53.8%) | 0       | 0.72 |
| Liver disorder| 64 (40.5%)     | 5 (3.2%)     | 52 (39.4%)  | 4 (3.0%)  | 12 (46.2%) | 1 (3.8%) | 0.75 |
| Anorexia      | 53 (33.5%)     | 9 (5.7%)     | 46 (34.8%)  | 8 (6.1%)  | 7 (26.9%)  | 1 (3.8%) | 0.8 |
| Nausea        | 18 (11.4%)     | 1 (0.6%)     | 17 (12.9%)  | 1 (0.8%)  | 1 (3.8%)  | 0       | 0.57 |
| Malaise       | 17 (10.8%)     | 0            | 11 (8.3%)   | 0         | 6 (23.1%)  | 0       | 0.027 |
| Kidney disorder| 7 (4.4%)     | 0            | 5 (3.8%)    | 0         | 2 (7.7%)  | 0       | 0.38 |

CTCAE: common terminology criteria for adverse events.
INPULSIS trials. Azuma et al. reported the Japanese subset analysis of the INPULSIS trial, showing that abnormal hepatic function and increased liver enzymes were more frequent in the Japanese subjects compared with overall population.18,19 Ikeda et al.20 reported an association between BMI and liver dysfunction due to nintedanib, which indicated that the dose of nintedanib should be adjusted according to BMI of patients. In our study, patients with severe IPF had significantly lower body weight and BMI than those with moderate disease. In addition, they were more likely to have received previous treatment, such as corticosteroid and immunosuppressants, which might contribute to the high incidence of liver disorders. In comparison to the moderate group, the severe group tended to experience more side effects although the difference was not statistically significant except for malaise.

There were some big limitations in our study. First, as this study was retrospective, a selection bias might exist concerning the introduction of nintedanib for the patients with IPF. Sample size/power analysis was not performed. This effect may result in an inadequate analysis of the severe group. Second, the number of patients in the severe group was too small to conclude whether nintedanib is effective for these patients. Pulmonary function assessment is not adequate due to more acute exacerbations and death events in the severe group. Third, ΔFVC could be compared before and after the introduction of nintedanib only in a limited number of patients. Fourth, the follow-up time was short in our study. The discontinuation rate of nintedanib was as high as 47.5% and almost 20% had the dose reduced which makes the assessment of the efficacy challenging in this study.

Conclusion

In this real-world study, we observed ΔFVC similar to those shown in the INPULSIS trials. On the contrary, the rate of acute exacerbation was higher, especially in the patients with severe IPF. Further clinical data are required to evaluate the clinical benefit of nintedanib, especially in patients with severe IPF and those receiving LTOT.

Acknowledgements

The authors are grateful to the patients and their family and medical staff who contributed to this study.

Author contributions

M.D. prepared the article and made contributions to acquisition of data. H.T. made a concept of this study; H.T. and K.T. conducted statistical analysis. M.I., Y.I., T.S., F.O., and C.T. treated and observed patients in Hirosaki University; T.M. and Y.H. treated and observed patients in Hirosaki Central Hospital; Sh.T. evaluated the CT image of the patients included this study. S.T. advised and revised statistical analysis critically for important intellectual content and reviewed the article. All authors read and approved the final article.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval

Ethical approval for this study was obtained from Hirosaki University Research Ethics Review Committee prior to the study (approval number: 2018-1203).

Ethical approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the ethics committee of Hirosaki University (approval number: 2018-1203). Because this was a retrospective cohort study, informed consent was waived. Opt out was done on the website of Hirosaki University.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent

Informed consent was not sought for the present study because this was a retrospective cohort study, and informed consent was waived. Opt out was posted on the website of Hirosaki University.

ORCID iDs

Hisashi Tanaka https://orcid.org/0000-0003-2009-0210
Chiori Tabe https://orcid.org/0000-0001-9022-8700
Yoshihito Tanaka https://orcid.org/0000-0002-0721-2239

Supplemental material

Supplemental material for this article is available online.

References

1. Raghu G, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006; 3(4): 285–292.
2. Kim DS, Collard HR and King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006; 3(4): 285–292.
3. Natsuizaka M, Chiba H, Kuronuma K, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med 2014; 190(7): 773–779.
4. Chaudhary NL, Roth GJ, Hilberg F, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. *Eur Respir J* 2007; 29(5): 976–985.

5. Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. *Eur Respir J* 2015; 45(5): 1434–1445.

6. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good anti-tumor efficacy. *Cancer Res* 2008; 68(12): 4774–4782.

7. Wollin L, Maillet I, Quesniaux V, et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. *J Pharmacol Exp Ther* 2014; 349(2): 209–220.

8. Roth GJ, Binder R, Colbatzky F, et al. Nintedanib: from discovery to the clinic. *J Med Chem* 2015; 58(3): 1053–1063.

9. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. *N Engl J Med* 2011; 365(12): 1079–1087.

10. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med* 2014; 370(22): 2071–2082.

11. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. *Ann Intern Med* 2012; 156(10): 684–695.

12. Wuyts WA, Kolb M, Stowasser S, et al. First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of ≤50% of predicted value. *Lung* 2016; 194(5): 739–743.

13. Yoon HY, Park S, Kim DS, et al. Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis. *Respir Res* 2018; 19(1): 203.

14. Abe M, Tsushima K, Sakayori M, et al. Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study. *Drug Des Devel Ther* 2018; 12: 3369–3375.

15. Tzouvelekis A, Karampitsakos T, Kontou M, et al. Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: a real-life observational study in Greece. *Pulm Pharmacol Ther* 2018; 49: 61–66.

16. Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. *Eur Respir J* 2011; 37(2): 356–363.

17. Ryerson CJ, Cottin V, Brown KK, et al. Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. *Eur Respir J* 2015; 46(2): 512–520.

18. Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS trials. *Respir Med* 2016; 113: 74–79.

19. Azuma A, Taniguchi H, Inoue Y, et al. Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: a subgroup analysis of the INPULSIS® randomized trials. *Respirology* 2017; 22(4): 750–757.

20. Ikeda S, Sekine A, Baba T, et al. Hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis: a single-center experience. *Respir Investig* 2017; 55(1): 51–54.